Group 1 - The core point of the article highlights the performance of the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217), which experienced a decline of 1.00% with a trading volume of 1.126 billion yuan on November 14 [1] - The fund's shares increased by 41 million to a total of 3.764 billion shares, with a notable increase of 341 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 5.595 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with managers Liu Weilin and Jiao Wenlong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 48.64%, with a monthly return of 4.74% [1]
11月14日港股通创新药ETF工银（159217）份额增加4100.00万份
Xin Lang Cai Jing·2025-11-17 01:11